CTLA4 and Miyoshi myopathy: Data on MM treated with anti-CTLA-4, anti-PD-1, or a combination of both agents show a median OS of 9.6, 11.5, and 11 months which is comparable with the 55 patients in our cohort who were treated with either immune or targeted therapy and had median OS of 12 months [16,34].